Compare Johnson & Johnson (JNJ) vs Marriott International Inc (MAR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Marriott International Inc — how do they compare? Johnson & Johnson trades at $259.54 (market cap $618.09B), while Marriott International Inc trades at $363.76 (market cap $94.16B). The key difference: Johnson & Johnson is far larger — about 6.6× Marriott International Inc 's market cap, and Johnson & Johnson pays the higher dividend (2.09%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson & Johnson for 129 Days and Marriott International Inc for 164 Days on average.
| JNJ | MAR | |
|---|---|---|
Market Cap | $618.09B | $94.16B |
Volume | 6,050,983 | 996,176 |
Sector | Health | Consumer Cyclical |
52-Week High | $278.43 | $402.54 |
52-Week Low | $186.00 | $259.04 |
Typical Hold Time | 129 Days | 164 Days |
Enterprise Value | $646.37B | $111.47B |
Dividend Yield | 2.09% | 0.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $258.45, up 1.44% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $94.19B revenue, 21.48% net margin, and robust cash flow. Analyst consensus is bullish with a $286.53 price target, though technical indicators show resistance near $260. Recent news highlights pipeline strength including Icotyde's potential $4.5B peak sales.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and competitive pressures. The stock presents value near current levels with 10.7% upside to consensus target, though technical weakness suggests potential near-term consolidation. Long-term growth drivers include oncology portfolio and Ottava surgical system development.
Marriott International (MAR) trades at $356.5, down 1.32% on the day, with a bullish technical signal supported by moving averages. Revenue grew to $26.19B in 2025, with a net income margin of 9.62%. Recent earnings beat expectations in Q1 and Q2 2026, while Q3 results are pending. The company maintains strong cash flow from operations at $3.21B and announced a dividend of $0.73 per share payable in September 2026.
The outlook is positive with a consensus price target of $386.71, implying upside. Risks include high debt levels and competitive pressures. Analyst sentiment is mixed with 44% buy ratings, but institutional interest remains strong, supporting a cautiously optimistic view for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Read more on MAR →
